Related Experiment Video
Updated: May 7, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Effect of simvastatin on hemostasis in patients with isolated hypertriglyceridemia
Robert Krysiak1, Boguslaw Okopien
1Department of Clinical Pharmacology, Medical University of Silesia, Katowice, Poland.
Insights
Simvastatin treatment positively impacts blood clotting and clot breakdown in patients with high triglycerides. This statin therapy may offer benefits for individuals with elevated triglyceride levels and associated cardiovascular risks.
Area of Science:
- Cardiovascular Medicine
- Hematology
- Pharmacology
Background:
- Elevated triglyceride levels are linked to early-onset and accelerated coronary artery disease.
- Hypertriglyceridemia is a significant risk factor for cardiovascular complications.
Purpose of the Study:
- To investigate the effects of simvastatin on coagulation and fibrinolysis in patients with isolated hypertriglyceridemia.
- To assess simvastatin's impact on hemostatic variables in this patient population.
Main Methods:
- A 90-day randomized controlled trial involving 39 patients with hypertriglyceridemia and peripheral artery sclerosis.
- Patients received either 40 mg daily simvastatin or a placebo.
- Assessed plasma lipids, glucose homeostasis, and hemostatic variables at baseline and post-treatment.
Main Results:
- Simvastatin significantly reduced plasma levels/activity of fibrinogen, factor VII, and plasminogen activator inhibitor-1.
- No significant reduction in von Willebrand factor levels was observed with simvastatin.
- Simvastatin tended to prolong prothrombin and partial thromboplastin times, indicating altered coagulation dynamics.
Conclusions:
- Statin treatment, specifically simvastatin, exerts a multifaceted influence on coagulation and fibrinolysis.
- These findings suggest potential cardiovascular benefits of simvastatin in patients with isolated hypertriglyceridemia.
Backgrounds/Aims:
Elevated triglyceride levels seem to predispose to the earlier development and accelerated progression of coronary artery disease. In our study, we assessed for the first time whether simvastatin treatment affects coagulation and fibrinolysis in patients with isolated hypertriglyceridemia.
Methods:
The study included 39 patients with elevated triglyceride levels and peripheral artery sclerosis, treated for 90 days with either simvastatin (40 mg daily) or placebo. Plasma lipids, glucose homeostasis markers and hemostasic variables were assessed at baseline and after treatment.
Results:
Simvastatin, but not placebo, administered to these patients reduced plasma levels/activity of fibrinogen (from 3.5 ± 0.4 to 2.8 ± 0.3 g/l, p < 0.01), factor VII (from 144.2 ± 16.9 to 112.5 ± 14.0%, p < 0.01) and plasminogen activator inhibitor-1 (from 76.9 ± 13.5 to 50.2 ± 9.2 ng/ml, p < 0.001), without a significant reduction in von Willebrand factor levels, and tended to prolong the prothrombin and partial thromboplastin times.
Conclusion:
Our results suggest that statin treatment produces a multidirectional effect on coagulation and fibrinolysis in patients with isolated hypertriglyceridemia and that this treatment may bring some benefits to patients with elevated triglyceride levels.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Atherosclerosis III: Management
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Cholesterol: Significance and Regulation
Considering cholesterol and...
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins